Cancer Medicine (May 2023)

Differences in DNA damage repair gene mutations between left‐ and right‐sided colorectal cancer

  • Wei Huang,
  • Wenliang Li,
  • Ning Xu,
  • Hui Li,
  • Zihan Zhang,
  • Xiaolong Zhang,
  • Tingting He,
  • Jicheng Yao,
  • Mian Xu,
  • Qingqing He,
  • Lijie Guo,
  • Sen Zhang

DOI
https://doi.org/10.1002/cam4.5716
Journal volume & issue
Vol. 12, no. 9
pp. 10187 – 10198

Abstract

Read online

Abstract Background Colorectal cancer (CRC) is the third leading cause of cancer‐related deaths worldwide. Studies have shown that the DNA damage response (DDR) mutation is strongly associated with microsatellite instability (MSI) status and is an indication for patients with CRCs receiving immune checkpoint inhibitor (ICI) treatment. However, DDR mutation in microsatellite stable (MSS) CRC remains unclear. Methods In this study, Fisher's exact test, Student'st‐test, Wilcoxon rank‐sum test and Cox proportional hazards regression model were performed, and a p value of < 0.05 was considered statistically significant. Results The most common gene alterations were APC (77%), TP53 (73%), KRAS (48%), and PIK3CA (25%). The mutationfrequency of APC and TP53 in left‐sided CRC was significantly higher than that for right‐sided CRC, while the mutation frequency of PIK3CA, ACVR2A, FAT4, and RNF43 in right‐sided CRC was significantly higher than that for left‐sided CRC. DDR mutations occurred in100% of MSI CRCs and in 83.77% of MSS CRCs, with the most frequently mutated DDR genes being ARID1A (7.5%), ATM (5.7%,) and BRCA2 (2.6%). When right‐ and left‐sided CRCs were compared, no significant difference was observed for DDR genes and pathways. A survival analysis indicated that the DDR mutation was not associated with overall survival (OS) in MSS CRCs, while left‐sided patients with homologous recombination repair (HRR) pathway mutations had a significantly prolonged OS compared with right‐sided CRCs. Conclusions Here, we found that stage and grade were statistically significant independent prognostic factors in the left‐sided CRC and the right‐sided CRC, recommending treatment for these patients stratified by stage. For the future, utilizing DDR gene defects for expanding treatment options and improving prognosis is an issue worth exploring.

Keywords